GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aptevo Therapeutics
The shares of Aptevo, an oncology biotech, reflect the potential of its platform for creating bispecific antibodies. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
Aptevo Therapeutics is a biotech company developing bispecific antibodies for the treatment of cancer, specifically acute myeloid leukemia. We have classified it in the Pharma: Immunology category. The chart below shows how the market values innovative approaches in immuno-oncology.
Broad Market Index - GURU.Markets
Aptevo Therapeutics is a biotech company developing a new class of bispecific antibodies for cancer treatment. Its innovative platform makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Aptevo compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
APVO - Daily change in the company's share price Aptevo Therapeutics
For Aptevo Therapeutics Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
Aptevo Therapeutics develops new immunotherapeutic drugs for the treatment of cancer. Immuno-oncology biotechnology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and dynamics of APVO stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Aptevo Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aptevo Therapeutics
For Aptevo Therapeutics, the year-over-year performance is a reflection of its ADAPTIR™ bispecific antibody platform. Its 12-month market cap is entirely dependent on clinical trial data. Success with its lead candidate for acute myeloid leukemia could be a breakthrough and a validation of its technology.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech, Aptevo is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment, opening up new opportunities in immuno-oncology. Its year-over-year market capitalization growth reflects investor confidence in its technology platform. Successful clinical data could lead to exponential growth, regardless of the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aptevo Therapeutics
Aptevo is a biotech company with a unique platform for creating bispecific antibodies. Its monthly performance is entirely dependent on progress in its clinical oncology programs. Research data is the primary driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Aptevo Therapeutics develops bispecific antibodies for cancer treatment. Its ADAPTIR platform enables the creation of drugs that simultaneously target two targets. The company's valuation depends on clinical success. The immunotherapy sector's price chart reflects overall investor interest in this cutting-edge field, which provides the backdrop for the valuation of Aptevo's technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aptevo Therapeutics develops immuno-oncology drugs. Like many biotech companies, its shares follow the clinical trials calendar. Its monthly price action is largely independent of overall market sentiment, reflecting investor confidence in the company's breakthrough technologies, as the chart clearly demonstrates.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aptevo Therapeutics
Aptevo Therapeutics is developing innovative bispecific antibodies for cancer treatment. Its weekly stock price, like that of many biotech companies, reflects progress in clinical trials. Positive data can trigger a sharp rise, while failures can trigger an equally sharp decline.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Aptevo Therapeutics develops innovative immuno-oncology drugs. Like many biotech companies, its shares are highly volatile and dependent on research and development news. The chart allows us to distinguish Aptevo-specific events from general fluctuations in the healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aptevo Therapeutics is a company developing immuno-oncology drugs. Its stock is a classic biotech whose performance depends on trial news. The chart clearly demonstrates this disconnect from the broader market and its macroeconomic drivers.
Market capitalization of the company, segment and market as a whole
APVO - Market capitalization of the company Aptevo Therapeutics
Aptevo Therapeutics' market capitalization is the investor valuation of its biotech platform, ADAPTIR. The chart shows how the market values its lead drug, which treats a rare type of leukemia. Its high volatility and low price reflect both the potential of its technology and the risks associated with commercialization and drug development.
APVO - Share of the company's market capitalization Aptevo Therapeutics within the market segment - Pharma immune
Aptevo Therapeutics develops bispecific antibodies for cancer treatment. Its market share in the immuno-oncology sector is small, but it relies on cutting-edge technology. Its market capitalization is based on the valuation of its ADAPTIR platform, which enables the creation of antibodies that simultaneously target two different targets.
Market capitalization of the market segment - Pharma immune
This chart shows the total market capitalization of the entire biotech sector specializing in immune therapy. For Aptevo Therapeutics, with its bispecific antibody platform, this line is a map of the future of oncology. The chart's growth reflects investors' belief that new technologies will enable the creation of more precise and powerful cancer treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aptevo Therapeutics develops bispecific antibodies for cancer treatment. Its market capitalization is the valuation of its innovative platform. This represents the market share of its technologies, which enable the creation of "smart" drugs that attack tumors from both sides.
Book value capitalization of the company, segment and market as a whole
APVO - Book value capitalization of the company Aptevo Therapeutics
Aptevo Therapeutics develops bispecific antibodies for cancer treatment. Its book value is its scientific and financial capital. It consists of cash for R&D and the value of its patented ADAPTIR platform. How has this capital changed as the technology has developed? The chart below shows.
APVO - Share of the company's book capitalization Aptevo Therapeutics within the market segment - Pharma immune
Aptevo Therapeutics develops bispecific antibodies for cancer treatment. Its innovative ADAPTIR platform requires a significant resource base, including in-house R&D centers and investments in manufacturing processes. The chart shows the company's share of the physical infrastructure required to create next-generation immunotherapy.
Market segment balance sheet capitalization - Pharma immune
Aptevo Therapeutics is an oncology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Aptevo focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Aptevo's assets are not factories, but the ADAPTIR™ biotech platform for creating bispecific antibodies that can simultaneously attack two targets, which holds promise in oncology. The book value reflects the material base for these complex scientific developments. The chart illustrates its scale in the biotech world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aptevo Therapeutics
Aptevo Therapeutics is a biotech company developing a new class of immunotherapeutic drugs. Its market value is derived from the valuation of its unique scientific platform, ADAPTIR. Investors are buying a stake in a potential breakthrough in cancer treatment.
Market to book capitalization ratio in a market segment - Pharma immune
Aptevo Therapeutics is a biotech company developing a new class of immunotherapeutic drugs. Its high valuation on this chart reflects its unique scientific platform, ADAPTIR, and its potential for treating cancer and autoimmune diseases.
Market to book capitalization ratio for the market as a whole
Aptevo Therapeutics develops immuno-oncology drugs. Its key asset is the bispecific antibody platform ADAPTIR. The company's market value reflects investors' faith in its technology. This chart shows the premium the market is willing to pay for innovative platforms capable of generating multiple potential drugs.
Debts of the company, segment and market as a whole
APVO - Company debts Aptevo Therapeutics
Aptevo, a biotech company with a platform for creating bispecific antibodies, funds its oncology programs through partnerships and raised capital. This chart shows how the company uses its financial resources to advance its research through the costly stages of clinical trials.
Market segment debts - Pharma immune
Aptevo Therapeutics is a biotech company developing bispecific antibodies for cancer treatment. Its ADAPTIR platform enables the creation of drugs that simultaneously target cancer cells and activate the immune system. The chart shows how the company is funding the development of its complex technology platform and advancing its candidates through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aptevo Therapeutics
Aptevo Therapeutics is developing novel bispecific antibodies for cancer treatment. Its ADAPTIR platform requires significant and ongoing investment in research and clinical trials. This chart illustrates the company's reliance on debt to finance its oncology drug portfolio, which is typical for biotech companies.
Market segment debt to market segment book capitalization - Pharma immune
Aptevo Therapeutics develops bispecific antibodies for cancer treatment. Immuno-oncology is a cutting-edge but highly expensive field. This chart shows how the company finances its innovative research. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector, reflecting its financial risks.
Debt to book value of all companies in the market
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment. This is a cutting-edge, but very expensive, field of immuno-oncology. How heavily does the company rely on debt financing to advance its drug candidates? This chart of total debt in the economy provides context for assessing its financial strategy and risks.
P/E of the company, segment and market as a whole
P/E - Aptevo Therapeutics
Aptevo Therapeutics is a biotech company developing novel immunotherapeutic drugs for cancer treatment using its ADAPTIR platform. This chart shows how investors value its technology. The valuation is heavily dependent on progress in clinical trials and partnerships with major pharmaceutical companies.
P/E of the market segment - Pharma immune
Aptevo Therapeutics is a biotech company developing novel immuno-oncology drugs based on its ADAPTIR platform, which enables the creation of bispecific antibodies. This chart illustrates the average valuation in the immuno-oncology sector, where investors are betting on innovative platforms to create next-generation cancer drugs.
P/E of the market as a whole
Aptevo Therapeutics is a biotech company developing a new generation of immunotherapeutic drugs for cancer treatment based on its ADAPTIR platform. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether APVO's high valuation is based on faith in its unique technology or is moving in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aptevo Therapeutics
Aptevo Therapeutics is developing new bispecific antibodies for cancer treatment. This technology simultaneously targets cancer cells and activates the immune system. This chart shows how much investors believe in the potential of this innovative platform and its ability to lead to the development of effective oncology drugs.
%20P%2FE%20Aptevo%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aptevo-Therapeutics&v=1772618297561 "Chart of the company's future (projected) P/E Aptevo Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Aptevo Therapeutics is developing novel bispecific antibodies for cancer treatment. This technology simultaneously attacks cancer cells and activates the immune system. The chart shows average profitability expectations in the sector, helping to understand the market's confidence in the breakthrough potential of Aptevo's ADAPTIR platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772618297562 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Aptevo Therapeutics develops new immunotherapeutic drugs for the treatment of oncology. The company uses a proprietary technology platform. This biotech risk appetite chart reflects the extent to which investors believe in the potential of new drug discovery platforms and are willing to fund their development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772618297572 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aptevo Therapeutics
Aptevo Therapeutics develops new immunotherapeutic drugs for cancer treatment using its proprietary ADAPTIR technology. Its financial metrics include R&D expenses. This chart shows how much the company is investing in creating the next generation of drugs that harness the body's immune system to fight cancer.
Profit of companies in the market segment - Pharma immune
Aptevo Therapeutics develops innovative bispecific antibodies for cancer treatment. Its technology simultaneously targets cancer cells and activates the immune system. This chart shows the overall profitability of the immunopharmaceutical sector, which is at the forefront of the fight against cancer and attracts significant investment in research.
Overall market profit
Aptevo Therapeutics develops new immunotherapy methods for the treatment of oncology. The company is at the forefront of biotechnology, and its future depends on the success of clinical trials. The overall economic environment, illustrated by this chart, does not directly impact the scientific process or the demand for innovative cancer drugs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aptevo Therapeutics
Aptevo Therapeutics is developing a novel bispecific immunotherapy for cancer treatment. The company's future profitability depends entirely on the success of its ADAPTIR platform in clinical trials. This chart reflects analysts' risky bet that Aptevo's technology will prove effective and safe in the fight against cancer.
%20profit%20of%20the%20company%20Aptevo%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aptevo-Therapeutics&v=1772618297608 "Graph of future (projected) profit of the company Aptevo Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment. This technology simultaneously targets cancer cells and activates the immune system to destroy them. The company's future depends on the success of its ADAPTIR™ platform. This chart shows revenue projections for the immunopharmaceuticals sector, helping to assess the potential of Aptevo's developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772618297609 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Aptevo Therapeutics is a biotechnology company developing novel immunotherapeutic drugs. Its success depends on progress in clinical trials and partnerships. This revenue expectation schedule impacts the overall investment climate and the willingness of large pharmaceutical companies and investors to invest in innovative developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772618297612 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aptevo Therapeutics
Aptevo Therapeutics is developing bispecific antibodies for the treatment of oncology. Revenue may be minimal at the clinical stage. This chart reflects investor valuation of its innovative ADAPTIR technology platform. Its significance reflects a bet on future breakthroughs in immuno-oncology.
P/S market segment - Pharma immune
Aptevo Therapeutics develops new immunotherapeutic drugs for cancer treatment using its proprietary ADAPTIR platform. This technology enables the creation of bispecific antibodies that can simultaneously attack tumor cells and activate the immune system. This chart displays the average revenue estimate for the sector, reflecting expectations for this platform.
P/S of the market as a whole
Aptevo Therapeutics is a biotech company developing immunotherapeutic drugs for the treatment of oncology. This chart highlights that the valuation of such research-stage companies reflects investors' faith in their scientific platform and future drugs, which contrasts sharply with the market average, where current revenue is the primary focus.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aptevo Therapeutics
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment. This technology allows for simultaneous attack of cancer cells and activation of the immune system. For such an innovative company, estimating future revenue is critical. It reflects investors' confidence in the potential of its ADAPTIR platform and the future commercial success of its oncology drug candidates.
%20P%2FS%20Aptevo%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aptevo-Therapeutics&v=1772618297624 "The graph of the company's future (projected) P/S Aptevo Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Aptevo Therapeutics develops bispecific antibodies for the treatment of oncology and hematological diseases. This chart reflects how investors assess the company's future revenues relative to the biotech sector. It demonstrates the market's confidence in its ADAPTIR technology platform and its ability to develop innovative immunotherapeutics.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772618297625 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment that can simultaneously attack two different targets. The company's future depends on the success of its innovative ADAPTIR platform. This market forecast chart reflects investor confidence that new approaches in immuno-oncology will lead to more effective drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772618297632 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aptevo Therapeutics
This figure reflects the revenue of Aptevo Therapeutics, a biotechnology company developing innovative immunotherapeutic drugs for the treatment of cancer. Being in the clinical stage, the company may not have stable sales revenue. Revenue may be generated through partnership fees and grants supporting its research.
Sales of companies in the market segment - Pharma immune
Aptevo Therapeutics develops bispecific antibodies for the treatment of cancer. Its current revenue may come from royalties or grants. Its future sales structure will depend entirely on which of its cancer-targeted candidates successfully completes clinical trials and reaches the market.
Overall market sales
Aptevo Therapeutics develops innovative bispecific antibodies for cancer treatment. The company is at the forefront of immuno-oncology. Its success depends solely on the results of clinical trials and the potential of its scientific platform. This market overview chart is irrelevant to assessing Aptevo's prospects in medical science.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aptevo Therapeutics
Aptevo Therapeutics is developing new immunotherapeutic drugs based on its ADAPTIR bispecific antibody platform for cancer treatment. Future revenue depends on the success of clinical programs and potential partnerships with major pharmaceutical companies. This chart shows analysts' forecasts for potential revenue from technology licensing or sales of future drugs.
%20sales%20of%20the%20company%20Aptevo%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aptevo-Therapeutics&v=1772618297679 "Schedule of future (projected) sales of the company Aptevo Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment. This chart shows the outlook for the immunotherapy sector. Do analysts expect new approaches like bispecific antibodies to drive growth in the overall oncology market? This helps assess the overall scientific and commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772618297687 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Aptevo Therapeutics is a biotech company developing immunotherapeutic drugs. Its success depends on the results of clinical trials and partnerships within the pharmaceutical industry. The general economic cycles reflected in this chart are not directly related to the fundamental drivers and risks associated with the development of innovative drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772618297696 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aptevo Therapeutics
Aptevo Therapeutics is a biotechnology company developing novel immunotherapeutics based on its ADAPTIR bispecific antibody platform. This chart reflects its financial performance at the clinical development stage. Profitability is a future goal and will depend on the success of its innovative approaches to treating oncological and autoimmune diseases.
Market segment marginality - Pharma immune
Aptevo Therapeutics Inc. is a biotechnology company developing novel immunotherapeutic drugs based on its ADAPTIR platform. This chart reflects the company's financial performance at the clinical stage, whose future profitability depends on the progress of its candidates for the treatment of oncological and autoimmune diseases.
Market marginality as a whole
Aptevo Therapeutics develops novel immunotherapeutic drugs for cancer treatment. The company operates at the forefront of biotechnology, requiring significant investment for its development. This total return chart reflects investor risk appetite, which increases in a strong economy, making it easier for innovative companies to raise capital.
Employees in the company, segment and market as a whole
Number of employees in the company Aptevo Therapeutics
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment. Its small team of scientists is its greatest asset. This chart shows how the biotech startup manages its resources during clinical development. Changes in staffing can signal progress or pauses in the company's key research programs.
Share of the company's employees Aptevo Therapeutics within the market segment - Pharma immune
Aptevo Therapeutics develops innovative bispecific antibodies for cancer treatment. This is a cutting-edge field of immuno-oncology, requiring a team of highly qualified scientists and bioengineers. This graph shows the company's market share, reflecting its scientific potential and the scale of its research in one of the most competitive fields of biotech.
Number of employees in the market segment - Pharma immune
Aptevo Therapeutics is developing bispecific antibodies for cancer treatment. This technology allows a single antibody to simultaneously bind to both cancer cells and immune cells, activating the immune response. The graph illustrates the company's work in the immunopharmaceutical sector. Aptevo's ADAPTIR platform represents a promising direction in immuno-oncology.
Number of employees in the market as a whole
Aptevo Therapeutics develops innovative immunotherapeutic drugs for cancer treatment. This is a high-tech field where progress depends on scientific discoveries. Given the overall labor market dynamics shown in this chart, Aptevo exemplifies a company where every scientist hired is an investment in potentially revolutionary treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aptevo Therapeutics (APVO)
Aptevo Therapeutics is a biotech company developing immunotherapeutic drugs for cancer treatment. Their key asset is the ADAPTIR platform. This chart illustrates the high market value placed on their technology. It shows the market capitalization per scientist, reflecting the value of their R&D platform in the competitive field of oncology.
%20of%20the%20company%20Aptevo%20Therapeutics%20(APVO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aptevo-Therapeutics-APVO&v=1772618297800 "Chart of market capitalization per employee (in thousands of dollars) of the company Aptevo Therapeutics (APVO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Aptevo Therapeutics (APVO) develops new immunotherapeutic drugs for cancer treatment. In this competitive field, this chart demonstrates how unique the market perceives the company's technology. A high score may indicate that their ADAPTIR platform is capable of creating bispecific antibodies with an improved efficacy and safety profile.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772618297830 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Aptevo Therapeutics develops innovative bispecific antibodies for cancer treatment. The company's value lies in its scientific platform. This chart demonstrates how the market perceives the potential of this technology for creating a new generation of immuno-oncology drugs, which accounts for its high market capitalization despite its relatively small research staff.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772618297862 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aptevo Therapeutics (APVO)
Aptevo Therapeutics is a biotech company developing new cancer treatments (immunotherapy). It is a clinical-stage R&D company. This chart shows the company's capital burn rate, not its profit. It reflects how much the company invests in each of its scientists working on the development of next-generation cancer drugs.
%20Chart%20Aptevo%20Therapeutics%20(APVO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aptevo-Therapeutics-APVO&v=1772618297877 "Company Profit Per Employee (in thousands of dollars) Chart Aptevo Therapeutics (APVO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Aptevo Therapeutics is developing new approaches in immuno-oncology. For research-stage biotech companies, return per employee is an indicator of the potential of their scientific platform. The chart illustrates how investment in a team of scientists can translate into future value, and how this compares to other companies working at the forefront of science.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772618297879 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Aptevo Therapeutics is a biotech company developing an immunotherapy (ADAPTIR) for cancer treatment. It's an R&D business at the cutting edge of science. Profitability per employee here is based on future potential, which depends on the success of trials. This chart, showing the average market revenue, only highlights how significantly the biotech model, based on burning capital for the sake of science, differs from the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772618297883 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aptevo Therapeutics (APVO)
Aptevo Therapeutics develops innovative immunotherapeutic drugs. Like many biotechs in the R&D stage, current revenue per employee can be low. The chart illustrates the potential: a successful drug discovery platform can lead to partnerships and licensing deals that generate high revenue with a small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aptevo-Therapeutics-APVO&v=1772618297894 "Sales chart per company employee Aptevo Therapeutics (APVO)")
Sales per employee in the market segment - Pharma immune
Aptevo Therapeutics is a clinical-stage biotech developing immunotherapy (bispecific antibodies) for the treatment of oncology. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of APVO's R&D staffing efficiency (burn rate) compared to other biotechs.
Sales per employee for the market as a whole
Aptevo Therapeutics is a biotech company developing novel immuno-oncology drugs. Their platform enables the creation of "smart" antibodies that target cancer cells. This chart reflects their R&D status. The company is in clinical trials, and its research team generates data, not sales revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Aptevo Therapeutics (APVO)
Aptevo (APVO) is a biotech company developing immunotherapy for cancer treatment. This chart shows the number of short positions. As with many early-stage biotechs, short positions reflect high risk: investors are betting that the company's technology will prove ineffective or unsafe when it moves to human trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aptevo-Therapeutics-APVO&v=1772618297947 "Short Shares Chart for the Company Aptevo Therapeutics (APVO)")
Shares shorted by market segment - Pharma immune
Aptevo Therapeutics (APVO) is a biotech company developing next-generation immunotherapeutic drugs (bispecific antibodies) for cancer treatment. This chart shows the total short position in the immuno-oncology sector. It reflects investor concerns about the high level of competition in this field and the risks of clinical trials.
Shares shorted by the overall market
Aptevo (APVO) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like APVO in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aptevo Therapeutics (APVO)
Aptevo Therapeutics (APVO) develops bispecific antibodies for cancer treatment. Their ADAPTIR platform enables the creation of new immunotherapies. This oscillator measures price momentum. It helps identify when the stock is "overheated" (above 70) due to positive data or "oversold" (below 30) due to capital dilution or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aptevo-Therapeutics-APVO&v=1772618297962 "RSI 14 indicator chart for the company's stock Aptevo Therapeutics (APVO)")
RSI 14 Market Segment - Pharma immune
Aptevo Therapeutics is a biotech company developing bispecific antibodies (ADAPTIR) for cancer treatment. This technology allows the antibody to attack tumors while simultaneously activating the immune system. This chart measures the overall momentum in the immunology biotech sector. It clearly shows when this entire niche is overhyped or oversold.
RSI 14 for the overall market
Aptevo Therapeutics (APVO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APVO (Aptevo Therapeutics)
Aptevo Therapeutics is a biotech company using its ADAPTIR platform to create bispecific antibodies that can "direct" the immune system to fight cancer. This chart shows the speculative average price target from analysts based on their assessment of the potential of this complex R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APVO-Aptevo-Therapeutics&v=1772618297977 "A chart showing analyst consensus forecasts for the expected stock price. APVO (Aptevo Therapeutics)")
The difference between the consensus estimate and the actual stock price APVO (Aptevo Therapeutics)
Aptevo is a biotech company developing a new generation of "bispecific" antibodies (the ADAPTIR platform) for the treatment of blood cancers. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this complex but promising R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APVO-Aptevo-Therapeutics&v=1772618297978 "A chart showing the difference between the consensus forecast and the actual stock price. APVO (Aptevo Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Aptevo (APVO) is a biotech company developing bispecific antibodies (ADAPTIR platform) for cancer immunotherapy. This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe new R&D platforms will breakthrough or whether they believe the market is fragmented by "big pharma."
Analysts' consensus forecast for the overall market share price
Aptevo Therapeutics is a biotech company developing bispecific antibodies that act as a "bridge" between immune cells and cancer cells to destroy them. This chart reflects the overall market "risk appetite." For Aptevo, a clinical-stage company with an innovative platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aptevo Therapeutics
Aptevo is a biotech R&D company focused on immuno-oncology. Their signature R&D platform (ADAPTIR) creates bispecific antibodies (that attack cancer in two ways). This is a moonshot bet on R&D. This chart is a pure indicator of their faith in R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Pharma immune
Aptevo Therapeutics (APVO) is developing bispecific antibodies using its ADAPTIR platform. These molecular bridges grip a cancer cell with one hand and an immune cell (T cell) with the other, pitting them against each other. They focus on treating blood cancers and solid tumors. This chart shows the segment average. It helps investors assess how this complex technology compares to the average market.
The AKIM Index for the overall market
Aptevo Therapeutics is a biotech company developing bispecific antibodies (ADAPTIR platform) for immuno-oncology. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, struggling for clinical success and funding, compares to overall trends.
